Results 91 to 100 of about 40,773 (330)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Signal Transduction and Targeted Therapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD).
Xuhui Bao, Yongjun Liang, Hanman Chang, Tianji Cai, Baijie Feng, Konstantin Gordon, Yuekun Zhu, Hailian Shi, Yundong He, Liyi Xie   +9 more
semanticscholar   +1 more source

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer

Nature Communications, 2022
Therapeutic targeting of KRAS-mutant colorectal cancer (CRC) is an unmet need. Here, we show that Proprotein Convertase Subtilisin/Kexin type 9 (PSCK9) promotes APC/KRAS-mutant CRC and is a therapeutic target.
C. Wong, Jian-Lin Wu, Fenfen Ji, W. Kang, Xiqing Bian, Huarong Chen, L. Chan, S. Y. Luk, Samuel Tong, Jiaying Xu, Qiming Zhou, Dabin Liu, Hao Su, Hongyan Gou, A. Cheung, K. To, Z. Cai, J. Shay, Jun Yu   +18 more
semanticscholar   +1 more source

Autocrine effects of PCSK9 on cardiomyocytes [PDF]

Basic Research in Cardiology, 2020
AbstractProprotein convertase subtilisin kexin type 9 (PCSK9) is in the focus of cardiovascular research due to its role in hepatic low density lipoprotein (LDL) clearance. However, extrahepatic expression of PCSK9 such as in cardiomyocytes and its regulation by oxidized LDL (oxLDL) put notion on extrahepatic effects of PCSK9 as well.
Annemarie Wolf, Hanna Sarah Kutsche, Rolf Schreckenberg, Martin Weber, Ling Li, Susanne Rohrbach, Rainer Schulz, Klaus-Dieter Schlüter   +7 more
openaire   +3 more sources

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Characterized as a chronic inflammatory disease of the large arteries, atherosclerosis is the primary cause of cardiovascular disease, the leading contributor of morbidity and mortality worldwide.
E. Punch, Justus Klein, P. Diaba-Nuhoho, H. Morawietz, M. Garelnabi   +4 more
semanticscholar   +1 more source

Systemic lupus erythematosus and cardiovascular disease

Journal of Internal Medicine, Volume 293, Issue 1, Page 48-62, January 2023., 2023
Abstract The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment and care, but cardiovascular disease (CVD) still remains an important clinical problem, since the risk of CVD in SLE is much higher than among controls.
Johan Frostegård
wiley   +1 more source

Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9? [PDF]

Journal of Medical Biochemistry, 2016
Background: Serum small dense LDL-cholesterol (sdLDLC) value is suggested to be an important risk factor for atherosclerosis. Since sdLDL-C changes may be related to PCSK9 and SREBP-2 functions, the aim of this study was to investigate correlations ...
Soltanmohammadi Elham, Piran Sadegh, Mohammadi Asghar, Hosseni Bita, Naseri Faezeh, Shabani Mohammad, Najafi Mohammad   +6 more
doaj  

Association of high proprotein convertase subtilisin/kexin type 9 antibody level with poor prognosis in patients with diabetes: a prospective study

Scientific Reports, 2023
In addition to pathogenic autoantibodies, polyclonal autoantibodies with unknown physiological roles and pathogenicity are produced in the body. Moreover, serum antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, which ...
Hiroki Yamagata, Aiko Hayashi, Yoich Yoshida, Masaya Koshizaka, Shunichiro Onishi, Tomohiko Yoshida, Takaki Hiwasa, Minoru Takemoto   +7 more
doaj   +1 more source

The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update [PDF]

, 2016
The clinical indications and guidelines for low-density lipoprotein (LDL)-apheresis set by the 1(st) Italian Consensus Conference held in Ostuni in 1990 and completed in 1992, but never published, are reported schematically.
Stefanutti, Claudia
core   +1 more source

Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells

Frontiers in Immunology, 2022
Immunotherapy especially immune checkpoint inhibitors (ICIs) has brought favorable clinical results for numerous cancer patients. However, the efficacy of ICIs in colorectal cancer (CRC) is still unsatisfactory due to the poor median progression-free ...
Rui Wang, Hongchuan Liu, P. He, Duopeng An, Xiaohan Guo, Xuyao Zhang, Mei-Yan Feng   +6 more
semanticscholar   +1 more source

Genetic and molecular architecture of familial hypercholesterolemia

Journal of Internal Medicine, Volume 293, Issue 2, Page 144-165, February 2023., 2023
Abstract Atherosclerotic cardiovascular disease is the leading cause of death globally. Despite its important risk of premature atherosclerosis and cardiovascular disease, familial hypercholesterolemia (FH) is still largely underdiagnosed worldwide. It is one of the most frequently inherited diseases due to mutations, for autosomal dominant forms, in ...
Marianne Abifadel, Catherine Boileau
wiley   +1 more source